Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 947-581-5 | CAS number: 2209852-19-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Oral: LD50 > 300 - < 2000 mg/kg bw, female rat, OECD TG 420, 2018
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24-07-2018 to 21-08-2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study performed under GLP. All relevant validity criteria were met.
- Justification for type of information:
- Information as to the availability of the in vivo study is provided in 'attached justification'.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 bis (Acute Oral Toxicity - Fixed Dose Procedure)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- inspected: July 2017 ; signature: November 2017
- Test type:
- fixed dose procedure
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Recognised supplier
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 8 - 12 weeks.
- Weight at study initiation: 150-162 g (300 mg/kg including sighting test; sentinel); 160-175 g (2000 mg/kg sighting test; sentinel); The weight variation did not exceed ±20% of the mean weight in the definitive test.
- Fasting period before study: Overnight before dosing and three to four hours after dosing.
- Housing: Group housed in groups of up to four in suspended solid-floor polypropylene cages furnished with woodflakes.
- Diet (e.g. ad libitum): Certified diet from recognised supplier, provided ad libitum (except for fasting period).
- Water (e.g. ad libitum): ad libitum (except for fasting period)
- Acclimation period: At least 5 days.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19 - 25
- Humidity (%): 30 - 70%
- Air changes (per hr): > 15 air changes per hour
- Photoperiod: 12 h light / 12 h dark
IN-LIFE DATES: From: To: 24-07-2018 to 21-08-2018 - Route of administration:
- oral: gavage
- Vehicle:
- arachis oil
- Details on oral exposure:
- VEHICLE
- Concentration in vehicle: The specific gravity was determined and used to calculate the appropriate dose volume for the required dose level. For the purpose of the 300 mg/kg dose level the test item was freshly prepared, as required, as a solution in arachis oil BP. Arachis oil BP was used because the test item did not dissolve/suspend in distilled water. For the purpose of the 2000 mg/kg dose level, the test item was used as supplied. The 300 mg/kg bw and 2000 mg/kg bw dose levels were treated stepwise. Singularly and in the absence of mortality or evident toxicity a further group of 4 was tested in the appropriate dose level.
The test item was formulated at concentrations of 30 mg/mL or dosed as supplied according to specific gravity of the test item. Formulations were prepared on the day of dosing.
- Amount of vehicle (if gavage): Test Item dose volume was 10 mL/kg (of bodyweight) in Arachis Oil BP or dosed as supplied at 2.35 mL/kg
- Justification for choice of vehicle: The vehicle was selected based on trial formulations performed.
- Lot/batch no. (if required): See full study report.
- Purity: BP grade.
MAXIMUM DOSE VOLUME APPLIED: 300 mg/kg bw dose level: 10 mL/kg of test item in vehicle (Arachis Oil BP) ; 2000 mg/kg bw dose level: 2.35 mL/kg of test item as supplied.
DOSAGE PREPARATION (if unusual): Not applicable. The test item was prepared in the vehicle. It was administered to the animals under a volume of 10 mL/kg in Arachis Oil BP (300 mg/kg bw) or 2.35 mL/kg as supplied (2000 mg/kg bw).
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: In the absence of data regarding the toxicity of the test item, 300 mg/kg was chosen as the starting dose based on guideline recommendations. - Doses:
- 300 mg/kg bw (initial sighting test and main study)
2000 mg/kg bw (initial sighting test and main study) - No. of animals per sex per dose:
- 300 mg/kg bw in Arachis Oil vehicle (starting dose) : 1 (sighting study) and 4 (main study) as applicable.
2000 mg/kg bw: 1 (sighting study) and 4 (main study) as applicable; total 5 per dose - based on guideline specified sequential testing strategy - Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical observations were made 0.5, 1, 2, and 4 hours after dosing and then daily for fourteen days. Morbidity and mortality checks were made twice daily. Individual body weights were recorded on Day 0 (the day of dosing) and on Days 7 and 14.
- Necropsy of survivors performed: yes - Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- > 300 - < 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- 300 mg/kg bw (sentinel and definitive test): No mortality
2000 mg/kg bw (sentinel and definitive test): Two mortalities on day 2 (2/5) - Clinical signs:
- other: 300 mg/kg bw (sentinel and definitive test): No signs of systemic toxicity were noted. 2000 mg/kg bw (sentinel and definitive test): Hunched posture on day of dosing and up to day 4 (3/5), ataxia (1/5) which ceased one day after dosing. Within the mortali
- Gross pathology:
- 300 mg/kg bw (sentinel and definitive test): No abnormalties were noted at necropsy.
2000 mg/kg bw (sentinel and definitive test): No abnormalties were noted at necropsy in two survivors. One survivor had ulceration of the non-glandular region of the stomach at the end of the observation period. Within the mortalities: patchy pallor of the liver was noted at necropsy - Interpretation of results:
- Category 4 based on GHS criteria
- Remarks:
- Criteria used for interpretation of results: EU
- Conclusions:
- Under the conditions of this study, the oral LD50 was estimated to be in the range of 300 - 2000 mg/kg bw in female Wistar rats.
- Executive summary:
The study was performed according to OECD TG 420 and EU Method B.1 bis Acute Toxicity (Oral) and in accordance with GLP to assess the acute oral toxicity of the test material following a single oral administration in the female Wistar strain rat by the fixed dose method. The test item was administered by oral gavage in an initial sighting study at 300 mg/kg bw in a solution in arachis oil BP and following an absence of toxicity then at 2000 mg/kg bw unchanged. Subsequently, at a further group of four fasted females was given a single oral dose of test item, at a dose level of 300 mg/kg body weight and/or 2000 mg/kg bw depending on the findings at the preceding dose level.Two mortalities were seen at a dose level of 2000 mg/kg on Day 2. There were no deaths noted at a dose level of 300 mg/kg. Signs of systemic toxicity noted at a dose level of 2000 mg/kg in the mortalities during the study were loss of righting reflex, lethargy, decreased respiratory rate and laboured respiration. Within survivors hunched posture (three of five) and ataxia was observed (in one of five at this dose level). All survivors gained bodyweight. There were no clinical signs of systemic toxicity at 300 mg/kg bw and all animals showed expected gains in bodyweight over the study period.Patchy pallor of the liver was noted at necropsy in the mortalities at a dose level of 2000 mg/kg. Ulceration of the non-glandular region of the stomach was noted at necropsy of one survivor. At 300 mg/kg bw there was no abnormalities noted. Under the conditions of this study, the oral LD50 was estimated to be in the range of 300 - 2000 mg/kg bw in the female Wistar rat.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- discriminating dose
- Value:
- 300 mg/kg bw
- Quality of whole database:
- The available information as a whole meets the tonnage driven information requirements of REACH.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
ORAL:
Key study : OECD TG 420, 2018 : The study was performed according to OECD TG 420 and EU Method B.1 bis Acute Toxicity (Oral) and in accordance with GLP to assess the acute oral toxicity of the test material following a single oral administration in the female Wistar strain rat by the fixed dose method. The test item was administered by oral gavage in an initial sighting study at 300 mg/kg bw in a solution in arachis oil BP and following an absence of toxicity then at 2000 mg/kg bw unchanged. Subsequently, at a further group of four fasted females was given a single oral dose of test item, at a dose level of 300 mg/kg body weight and/or 2000 mg/kg bw depending on the findings at the preceding dose level.Two mortalities were seen at a dose level of 2000 mg/kg on Day 2. There were no deaths noted at a dose level of 300 mg/kg. Signs of systemic toxicity noted at a dose level of 2000 mg/kg in the mortalities during the study were loss of righting reflex, lethargy, decreased respiratory rate and laboured respiration. Within survivors hunched posture (three of five) and ataxia was observed (in one of five at this dose level). All survivors gained bodyweight. There were no clinical signs of systemic toxicity at 300 mg/kg bw and all animals showed expected gains in bodyweight over the study period.Patchy pallor of the liver was noted at necropsy in the mortalities at a dose level of 2000 mg/kg. Ulceration of the non-glandular region of the stomach was noted at necropsy of one survivor. At 300 mg/kg bw there was no abnormalities noted. Under the conditions of this study, the oral LD50 was estimated to be in the range of 300 - 2000 mg/kg bw in the female Wistar rat.
INHALATION:
No data.
DERMAL:
No data.
Justification for classification or non-classification
The substance meets classification criteria under Regulation (EC) No 1272/2008 for acute toxicity: oral category 4: H302
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
